Skip to content
Shameless Cloning

Search Shameless Cloning

Search superinvestors, stocks, insiders and members of Congress

Q2 2026 13F · SEC CIK 1727492

Caligan Partners LP

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value
$2.1B
Reported positions
25
Top holdings a year, 3 yrs
+82.3%
Assets under management
$1.3B

Caligan Partners LP is a hedge fund that reported 25 positions worth $2.1B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Liquidia Corporation (LQDA, 31.2%), Revolution Medicines Inc (RVMD, 17.7%), Abivax SA (ABVX, 10.0%). A portfolio copying its top holdings returned 82.3% a year over the last 3 years, against 20.4% for the S&P 500.

Caligan Partners LP holdings all 25 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Caligan Partners LP 13F holdings
Stock% of 13F valueShare changeReported value
LQDALiquidia Corporation31.2%+0.0%$647.3M
RVMDRevolution Medicines Inc17.7%+18.7%$367.4M
ABVXAbivax SA10.0%+6.6%$207.6M
PCVXVaxcyte Inc6.1%+6.2%$127.2M
EXELExelixis Inc4.1%+0.0%$84.5M
TNGXTango Therapeutics Inc3.8%+3.8%$78.2M
AVTXAvalo Therapeutics Inc2.8%+93.5%$58.5M
XENEXenon Pharmaceuticals Inc2.6%-36.1%$53.7M
ADMAADMA Biologics, Inc.2.3%+20.4%$47.9M
LBRXLB Pharmaceuticals, Inc.2.3%+0.0%$46.7M
IMCRImmunocore Hldgs PLC2.1%—$43.9M
VRDNViridian Therapeutics Inc1.9%—$40.3M
VORVor Biopharma Inc1.7%+0.0%$35.4M
SABSSab Biotherapeutics Inc1.5%+0.0%$31.1M
IVAInventiva SACA1.5%+64.1%$30.9M
AURAAura Biosciences Inc1.5%+1769.9%$30.5M
TYRATyra Biosciences Inc1.2%-36.8%$25.8M
IRDOpus Genetics Inc1.2%+0.0%$25.0M
ANIKAnika Therapeutics Inc1.0%+0.0%$21.0M
SGMTSagimet Biosciences Inc0.9%—$19.3M
ARTVArtiva Biotherapeutics Inc0.8%—$16.8M
SNSEFaeth Therapeutics Inc0.8%+399.6%$15.7M
MBXMbx Biosciences Inc0.5%-76.4%$11.0M
VRCAVerrica Pharmaceuticals Inc0.3%+0.0%$5.7M
CLRBCellectar Biosciences Inc0.1%—$1.3M

What Caligan Partners LP bought and sold in Q2 2026, against Q1 2026.

New positions

Added to

Reduced

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year
+95.8% /yr
S&P 500 +20.1%
3 years
+82.3% /yr
S&P 500 +20.4%
5 years
—

A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter13F valuePositions
Q2 2026$2.1B25
Q1 2026$1.4B24
Q4 2025$1.1B20
Q3 2025$720.7M16
Q2 2025$515.1M16
Q1 2025$479.2M16
Q4 2024$394.9M14
Q3 2024$315.5M12
Q2 2024$428.0M13
Q1 2024$378.3M12
Q4 2023$296.5M11
Q3 2023$195.5M12

Questions about Caligan Partners LP's portfolio

What stocks does Caligan Partners LP own?

Caligan Partners LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 25 positions worth $2.1B. The largest are Liquidia Corporation (LQDA) at 31.2%, Revolution Medicines Inc (RVMD) at 17.7%, Abivax SA (ABVX) at 10.0%, Vaxcyte Inc (PCVX) at 6.1% and Exelixis Inc (EXEL) at 4.1%.

What did Caligan Partners LP buy last quarter?

In Q2 2026, Caligan Partners LP added a new position in Immunocore Hldgs PLC (IMCR), a new position in Viridian Therapeutics Inc (VRDN), a new position in Sagimet Biosciences Inc (SGMT), a new position in Artiva Biotherapeutics Inc (ARTV), a new position in Cellectar Biosciences Inc (CLRB), Aura Biosciences Inc (AURA) (+1769.9% shares), Faeth Therapeutics Inc (SNSE) (+399.6% shares) and Avalo Therapeutics Inc (AVTX) (+93.5% shares), compared with its Q1 2026 filing.

What did Caligan Partners LP sell last quarter?

In Q2 2026, Caligan Partners LP sold all of Mineralys Therapeutics Inc (MLYS), sold all of Spyre Therapeutics (SYRE), sold all of Maze Therapeutics Inc (MAZE), sold all of Xilio Therapeutics Inc (XLO), Mbx Biosciences Inc (MBX) (-76.4% shares), Tyra Biosciences Inc (TYRA) (-36.8% shares) and Xenon Pharmaceuticals Inc (XENE) (-36.1% shares), compared with its Q1 2026 filing.

How has Caligan Partners LP's portfolio performed?

A portfolio copying Caligan Partners LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +82.3% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +95.8% against +20.1%.

When is Caligan Partners LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Caligan Partners LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Caligan Partners LP manage?

Caligan Partners LP reported $1.3B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $2.1B.